Aurora Cannabis Inc. (ACB) Q2 FY2026 (period ended September 30, 2025) results reflect mixed performance with significant operational risks.
Financial Performance: Six-month Net Revenue increased to \(188.4M (from \)164.6M in 2024). However, the Net Loss widened substantially to (\(72.9M) for the three months versus (\)13.2M) in the prior year. Q2 Net Revenue was \(90.4M, driven primarily by Medical Cannabis revenue of \)70.5M, offsetting weakness elsewhere. Underlying operational strength is suggested by Q2 Adjusted EBITDA of $15.4M, a 42 percent quarter-over-quarter increase, and Adjusted Net
...